Patent Filed: Peptide Augmentation Technology
- lukemarshall93
- Jun 16
- 2 min read
Updated: Oct 29
Australian Patent Application 2025902422 filed 13 June, 2025
Great news!
Biotome has filed a provisional patent for our novel peptide modification technology that dramatically increases ELISA sensitivity without the complexity and costs of traditional conjugation methods.
This patent will protect the technology underlying our Helitope gastric cancer risk diagnostic.
The Problem with Peptide ELISAs
If you've worked with peptides, you know the challenges. Unlike big, sticky proteins, peptides don't play nicely with surfaces. They're often highly soluble, struggle with passive adsorption, and frequently fail to present epitopes in the correct orientation for maximum antibody binding.
Of course there are workarounds, but all of these have drawbacks (believe us, we have tried them all). Maleimide coupling, biotin-avidin systems, carbodiimide crosslinking, or conjugation to carrier proteins like BSA all add cost, complexity, and processing time. Carrier proteins create significant non-specific background binding, and degrade signal-to-noise ratios. Chemical crosslinkers can destroy and bury epitopes with steric hindrance.
Our Solution: Direct Peptide Modification
Our approach directly modifies peptides, eliminating traditional coupling agents entirely. No external conjugation chemistry is required.
The results speak for themselves:
Dramatically increased signal-to-noise ratio compared to conventional peptide ELISAs
Extremely low non-specific binding – critical for clinical diagnostics
Cost-effective manufacturing - universal, low-cost reagents
Compatibility with microplates and microsphere (bead) chemistries for multiplexed applications
Proven in Practice
This technology is the foundation of our Helitope CagA ELISA, now available as a research-use-only kit. Every peptide in the test uses our approach, delivering the sensitivity and specificity required for gastric cancer risk research.
Multiple Commercialisation Pathways
We're exploring several avenues to bring this technology to market:
Custom Peptide Manufacturing We handle the manufacture and modification, and ship optimised peptides – including simple protocols for creating benchtop ELISA's for research
Full-Service Diagnostic Development We handle everything: from epitope discovery through to prototype validation, leveraging our complete peptide-ELISA platform
Technology Licensing Direct licensing to peptide manufacturers or ELISA kit developers to integrate our approach into their products
Each pathway addresses different market needs while maximising the technology's impact across the diagnostics industry.
Strategic IP Protection
Over the next 12 months we will be generating supporting data to strengthen our claims.
Perfect Timing
We're announcing this patent filing as Biotome heads to BIO 2025 in Boston, where we'll be seeking partners across diagnostic development, vaccine optimisation, and strategic licensing.
For companies frustrated with traditional peptide-ELISA limitations, our technology offers a path to the sensitivity and reproducibility that clinical applications demand.
Looking Forward
We've solved the peptide-ELISA problem. It's time to get it in the hands of researchers.
We've removed the main technical barrier while keeping all the cost and flexibility advantages. This puts us in a strong position as precision medicine drives demand for better, cheaper diagnostics.
Tired of your peptide results not translating into diagnostics? Ready to discuss how peptide augmentation can enhance your diagnostic development?
Find us at BIO 2025 in Boston (June 16-19) as part of the Australian delegation, or contact us directly to explore partnership opportunities.
Contact: Samuel Lundin, Founder & CEO (info@biotome.com.au)
Patent Reference: Australian Patent Application 2025902422
